These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1097 related items for PubMed ID: 28069652

  • 1. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS, Huband MD, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224535
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.
    Sader HS, Castanheira M, Duncan LR, Flamm RK.
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):69-74. PubMed ID: 29789189
    [Abstract] [Full Text] [Related]

  • 5. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D, Stone GG.
    BMC Infect Dis; 2021 Jun 23; 21(1):600. PubMed ID: 34162341
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.
    Antimicrob Agents Chemother; 2017 Nov 23; 61(11):. PubMed ID: 28827415
    [Abstract] [Full Text] [Related]

  • 7. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
    Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF.
    Antimicrob Agents Chemother; 2016 Aug 23; 60(8):4743-9. PubMed ID: 27216074
    [Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
    Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.
    Antimicrob Agents Chemother; 2018 Jul 23; 62(7):. PubMed ID: 29760124
    [Abstract] [Full Text] [Related]

  • 9. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr 23; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
    Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.
    Antimicrob Agents Chemother; 2019 Apr 23; 63(4):. PubMed ID: 30670424
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF.
    J Antimicrob Chemother; 2018 Oct 01; 73(10):2777-2781. PubMed ID: 30010951
    [Abstract] [Full Text] [Related]

  • 12. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM, Domene Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, López Montesinos I, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP.
    Microbiol Spectr; 2021 Sep 03; 9(1):e0058521. PubMed ID: 34319141
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS, Castanheira M, Jones RN, Flamm RK.
    Diagn Microbiol Infect Dis; 2017 Mar 03; 87(3):261-265. PubMed ID: 28069328
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC, Stone GG.
    Ann Clin Microbiol Antimicrob; 2020 Apr 01; 19(1):14. PubMed ID: 32238155
    [Abstract] [Full Text] [Related]

  • 15. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS, Huband MD, Duncan LR, Flamm RK.
    Pediatr Infect Dis J; 2018 Jun 01; 37(6):549-554. PubMed ID: 29206750
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 01; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A.
    J Glob Antimicrob Resist; 2020 Mar 01; 20():334-338. PubMed ID: 31568882
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
    Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader HS.
    Antimicrob Agents Chemother; 2016 Apr 01; 60(4):2537-41. PubMed ID: 26810650
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
    Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M.
    Microb Drug Resist; 2021 Mar 01; 27(3):342-349. PubMed ID: 32762605
    [Abstract] [Full Text] [Related]

  • 20. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015.
    Castanheira M, Mendes RE, Sader HS.
    Antimicrob Agents Chemother; 2017 Mar 01; 61(3):. PubMed ID: 28031200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.